Korean J Blood Transfus.  2012 Apr;23(1):13-19.

Evaluation of RF300 for Leukoreduction of Red Blood Cells

Affiliations
  • 1Blood Service Headquarters, Korean Red Cross, Seoul, Korea. bs510@redcross.or.kr
  • 2Blood Transfusion Research Institute, Korean Red Cross, Seoul, Korea.
  • 3Dongbu Blood Center, Korean Red Cross, Seoul, Korea.

Abstract

BACKGROUND
Use of universal leukoreduction for prevention of leukocyte associated transfusion reactions is common practice in many countries. This study was conducted in order to evaluate the performance of a newly developed leukoreduction filter for red blood cells (RBCs), the RF300 (Kolon Industries, Inc, Gumi, Korea).
METHODS
Filtration time, RBC recovery, residual leukocyte count, and leukocyte removal rate were evaluated. To assess the quality of RBCs after filtration, percent hemolysis was monitored for a period of 21 days. Performance of the RF300 (N=78) was compared with that of the Bio-R O2 plus (Fresenius, Hamburg, Germany), the Pall Purecell RC (Pall Co., Washington, USA), and the Sepacell R-500N (Asahi, Tokyo, Japan).
RESULTS
The shortest filtration time was observed using the RF300 (P<0.05). Using the RF300, recovery of RBC was 96.5%, which was higher than that of two filters (P<0.05). Mean residual leukocyte count was 0.26x10(6)/unit, with a leukocyte removal rate of 3 log. Using the RF300, mean percent hemolysis was 0.32% at day 21, which was comparable with that of two filters, but lower than that of one filter (P<0.05).
CONCLUSION
The RF300 meets all established quality requirements for conduct of safe and effective leukoreduction of RBCs.

Keyword

RF300; Leukoreduction; Red blood cells
Full Text Links
  • KJBT
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr